Considering IFNG as a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intra-tumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, we investigated the expression of the predict signatures developed by Ayers et al. [39]. The gene discussed is IFNG; the disease is cancer.